Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses.

OBJECTIVE To evaluate the independent association between psoriasis and risk of diabetes and hypertension. DESIGN A prospective study of female nurses who were followed up from 1991 to 2005. SETTING Nurses' Health Study II, a cohort of 116 671 US women aged 27 to 44 years in 1991. PARTICIPANTS The study included 78 061 women who responded to a question about a lifetime history of physician-diagnosed psoriasis in 2005. Women who reported a diagnosis of diabetes or hypertension at baseline were excluded. Main Outcome Measure New diagnosis of diabetes or hypertension, obtained from biennial questionnaires. RESULTS Of the 78 061 women, 1813 (2.3%) reported a diagnosis of psoriasis. During the 14 years of follow-up, a total of 1560 incident cases (2%) of diabetes and 15 724 incident cases (20%) of hypertension were documented. The multivariate-adjusted relative risk of diabetes in women with psoriasis compared with women without psoriasis was 1.63 (95% confidence interval, 1.25-2.12). Women with psoriasis were also at an increased risk for the development of hypertension (multivariate relative risk, 1.17; 95% confidence interval, 1.06-1.30). Age, body mass index, and smoking status did not significantly modify the association between psoriasis and risk of diabetes or hypertension (P values for interaction, > or =.07). CONCLUSIONS In this prospective analysis, psoriasis was independently associated with an increased risk of diabetes and hypertension. Future studies are needed to find out whether psoriasis treatment will reduce the risk of diabetes and hypertension.

[1]  J. Meyerovitch,et al.  Association between Psoriasis and the Metabolic Syndrome , 2008, Dermatology.

[2]  Erin G Harper,et al.  Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines , 2007, Current rheumatology reports.

[3]  W. Aronow,et al.  Incidence of New Stroke or New Myocardial Infarction or Death at 39-Month Follow-Up in Patients with Diabetes Mellitus, Hypertension or Both with and without Microalbuminuria , 2007, Cardiology.

[4]  Anna Viner,et al.  The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. , 2007, Journal of the American Academy of Dermatology.

[5]  E. Schiffrin,et al.  Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. , 2007, Clinical science.

[6]  E. Sijbrands,et al.  Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients. , 2007, Atherosclerosis.

[7]  M. Rizzo,et al.  Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. , 2006, Archives of medical research.

[8]  Daniel B. Shin,et al.  Prevalence of cardiovascular risk factors in patients with psoriasis. , 2006, Journal of the American Academy of Dermatology.

[9]  Daniel B. Shin,et al.  Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.

[10]  C. Ritchlin,et al.  Metabolic disorders in patients with psoriasis and psoriatic arthritis , 2006, Current rheumatology reports.

[11]  M. Weichenthal,et al.  Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.

[12]  J. Tuomilehto,et al.  Screen-detected diabetes, hypertension and hypercholesterolemia as predictors of cardiovascular mortality in five populations of Asian origin: the DECODA study , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[13]  A. Syrenicz,et al.  Low-grade systemic inflammation and the risk of type 2 diabetes in obese children and adolescents. , 2006, Neuro endocrinology letters.

[14]  G. Ning,et al.  Serum CRP levels are equally elevated in newly diagnosed type 2 diabetes and impaired glucose tolerance and related to adiponectin levels and insulin sensitivity. , 2006, Diabetes research and clinical practice.

[15]  P. Mease,et al.  Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. , 2006, Journal of the American Academy of Dermatology.

[16]  J. Tuomilehto,et al.  The Impact of History of Hypertension and Type 2 Diabetes at Baseline on the Incidence of Stroke and Stroke Mortality , 2005, Stroke.

[17]  R. Stern,et al.  Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. , 2005, Journal of the American Academy of Dermatology.

[18]  S. Feldman,et al.  The comorbid state of psoriasis patients in a university dermatology practice , 2005, The Journal of dermatological treatment.

[19]  A. Kimball,et al.  The Psychosocial Burden of Psoriasis , 2005, American journal of clinical dermatology.

[20]  R. Stern,et al.  The prevalence of psoriasis in African Americans: results from a population-based study. , 2005, Journal of the American Academy of Dermatology.

[21]  Edward H Livingston,et al.  Effect of diabetes and hypertension on obesity-related mortality. , 2005, Surgery.

[22]  V. Ho.  The use of ciclosporin in psoriasis: a clinical review , 2004, The British journal of dermatology.

[23]  M. Goodfield,et al.  Objective assessment of compliance with psoriasis treatment. , 2004, Archives of dermatology.

[24]  P. Lisi,et al.  Statistical association between psoriasis and diabetes: Further results , 1975, Archives of Dermatological Research.

[25]  H. Ollendorff-Curth.  Psoriasis und Diabetes mellitus , 1966, Archiv für klinische und experimentelle Dermatologie.

[26]  Women's high CRP levels can predict hypertension. , 2004, Healthcare benchmarks and quality improvement.

[27]  J. Pankow,et al.  Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. , 2003, Diabetes.

[28]  J. Manson,et al.  C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.

[29]  E. Christophers.  Psoriasis − epidemiology and clinical spectrum , 2001, Clinical and experimental dermatology.

[30]  M. Lebwohl,et al.  The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. , 2001, Archives of dermatology.

[31]  T. Chu.  Better patient compliance in psoriasis. , 2000, The Practitioner.

[32]  R. Brodell,et al.  A corticosteroid-induced flare of psoriasis. How to control or, better yet, avoid. , 1999, Postgraduate medicine.

[33]  S. Chevret,et al.  Long-term safety of cyclosporine in the treatment of psoriasis. , 1996, Archives of dermatology.

[34]  W. Willett,et al.  Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. , 1992, Annals of epidemiology.

[35]  R. Freinkel,et al.  Systemic absorption of topical steroids. Metabolic effects as an index of mild hypercortisolism. , 1986, Archives of dermatology.

[36]  W. Willett,et al.  Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. , 1986, American journal of epidemiology.

[37]  M. H. Brownstein.  Psoriasis and diabetes mellitus. , 1966, Archives of dermatology.

[38]  R. Fusaro,et al.  PSORIASIS VULGARIS. I. A CLINICAL SURVEY OF THE ASSOCIATION WITH DIABETES MELLITUS. , 1964, Archives of dermatology.

[39]  S. H. Gibson,et al.  Diabetes and psoriasis. , 1956, A.M.A. archives of dermatology.